Epigenomics of ovarian cancer and its chemoprevention.
Epigenomics of ovarian cancer and its chemoprevention.
复制标题
DOI：
10.3389/fgene.2011.00067
复制
发表时间：
2011
影响因子：
3.7
通讯作者：
Tollefsbol TO
中科院分区：
文献类型：
--
作者：
Chen H;Hardy TM;Tollefsbol TO
卵巢癌是妇科癌症中的主要致死原因，其病因仍不明确。目前，治疗这种危及生命的疾病面临的两个主要障碍是缺乏用于早期检测的有效生物标志物以及初始化疗后的耐药性。与其他癌症类似，卵巢癌的发生和发展的特征是癌基因和肿瘤抑制基因因遗传和表观遗传机制而失调。虽然众所周知，由于卵巢癌的异质性等原因，通过遗传策略治疗卵巢癌具有挑战性，但卵巢癌所涉及的表观遗传机制的可逆性为治疗开辟了令人兴奋的新途径。因此，卵巢癌的表观基因组学已成为一个迅速发展的领域，引发了深入的研究。因此，对该领域的现状进行综述是很有必要的。在本分析中，我们将评估卵巢癌表观基因组学的现状，并将包括卵巢癌发展过程中涉及的表观遗传机制，如DNA甲基化、组蛋白修饰和非编码微小RNA。还将评估生物标志物的开发、耐药性的表观遗传基础以及卵巢癌化疗的改进。此外，天然化合物作为化疗中的表观遗传调节剂的潜在用途在卵巢癌治疗策略中显示出有前景的应用，有望走到前沿。
Ovarian cancer is a major cause of death among gynecological cancers and its etiology is still unclear. Currently, the two principle obstacles in treating this life threatening disease are lack of effective biomarkers for early detection and drug resistance after initial chemotherapy. Similar to other cancers, the initiation and development of ovarian cancer is characterized by disruption of oncogenes and tumor suppressor genes by both genetic and epigenetic mechanisms. While it is well known that it is challenging to treat ovarian cancer through a genetic strategy due in part to its heterogeneity, the reversibility of epigenetic mechanisms involved in ovarian cancer opens exciting new avenues for treatment. The epigenomics of ovarian cancer has therefore become a rapidly expanding field leading to intense investigation. A review on the current status of the field is thus warranted. In this analysis, we will evaluate the current status of epigenomics of ovarian cancer and will include epigenetic mechanisms involved in ovarian cancer development such as DNA methylation, histone modifications, and non-coding microRNA. Development of biomarkers, the epigenetic basis for drug resistance and improved chemotherapy for ovarian cancer will also be assessed. In addition, the potential use of natural compounds as epigenetic modulators in chemotherapy shows promise in moving to the forefront of ovarian cancer treatment strategies.